| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ImmuLogic Pharmaceutical Corporation, Waltham, MA 02154
Multiple sclerosis is an autoimmune disease of the central nervous system in which T cell reactivity to several myelin proteins, including myelin basic protein (MBP), proteolipid protein, and myelin oligodendrocyte glycoprotein (MOG), has been implicated in the perpetuation of the disease state. Experimental autoimmune encephalomyelitis (EAE) is used commonly as a model in which potential therapies for multiple sclerosis are evaluated. The ability of T cell epitope-containing peptides to down-regulate the disease course is well documented for both MBP- and proteolipid protein-induced EAE, and recently has been shown for MOG-induced EAE. In this study, we describe a novel EAE model, in which development of severe disease symptoms in (PL/J x SJL)F1 mice is dependent on reactivity to two different immunizing Ags, MBP and MOG. The disease is often fatal, with a relapsing/progressive course in survivors, and is more severe than would be predicted by immunization with either Ag alone. The MOG plus MBP disease can be treated postinduction with a combination of the MOG 41–60 peptide (identified as the major therapeutic MOG epitope for this strain) and the MBP Ac1–11[4Y] peptide. A significant treatment effect can also be obtained by administration of the MBP peptide alone, but this effect is strictly dose dependent. This MBP peptide does not treat the disease induced only with MOG. These results suggest that peptide immunotherapy can provide an effective means of mitigating disease in this model, even when the treatment is targeted to only one component epitope or one component protein Ag of a diverse autoimmune response.
This article has been cited by other articles:
|
|
 |
|
  J. Karman, H. H. Chu, D. O. Co, C. M. Seroogy, M. Sandor, and Z. Fabry Dendritic Cells Amplify T Cell-Mediated Immune Responses in the Central Nervous System J. Immunol., December 1, 2006; 177(11): 7750 - 7760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lobell, R. Weissert, S. Eltayeb, K. L. de Graaf, J. Wefer, M. K. Storch, H. Lassmann, H. Wigzell, and T. Olsson Suppressive DNA Vaccination in Myelin Oligodendrocyte Glycoprotein Peptide-Induced Experimental Autoimmune Encephalomyelitis Involves a T1-Biased Immune Response J. Immunol., February 15, 2003; 170(4): 1806 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lovegrove, G. J. Pettigrew, E. M. Bolton, and J. A. Bradley Epitope Mapping of the Indirect T Cell Response to Allogeneic Class I MHC: Sequences Shared by Donor and Recipient MHC May Prime T Cells That Provide Help for Alloantibody Production J. Immunol., October 15, 2001; 167(8): 4338 - 4344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. McFarland, A. A. Lobito, M. M. Johnson, G. R. Palardy, C. S. K. Yee, E. K. Jordan, J. A. Frank, N. Tresser, C. P. Genain, J. P. Mueller, et al. Effective Antigen-Specific Immunotherapy in the Marmoset Model of Multiple Sclerosis J. Immunol., February 1, 2001; 166(3): 2116 - 2121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Legge, B. Min, J. J. Bell, J. C. Caprio, L. Li, R. K. Gregg, and H. Zaghouani Coupling of Peripheral Tolerance to Endogenous Interleukin 10 Promotes Effective Modulation of Myelin-Activated T Cells and Ameliorates Experimental Allergic Encephalomyelitis J. Exp. Med., June 19, 2000; 191(12): 2039 - 2052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Falk, O. Rotzschke, L. Santambrogio, M. E. Dorf, C. Brosnan, and J. L. Strominger Induction and Suppression of an Autoimmune Disease by Oligomerized T Cell Epitopes: Enhanced in Vivo Potency of Encephalitogenic Peptides J. Exp. Med., February 21, 2000; 191(4): 717 - 730. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
